Two-step schedule of anti-tumor immnunotherapy: anti-inflammatory treatment and dendritic cells-based vaccination.

PAULA CHIARELLA; JUAN BRUZZO; GABRIELA FERNANDEZ; VERMEULEN MONICA; MARISA VULCANO; OSCAR D. BUSTUOABAD; RAUL A. RUGGIERO

Rio de Janeiro- Brasil

Congreso; 13th International Congress of Immunology; 2007

Although animals can be prophylactically immunized against the growth of tumor implants, most of the attempts to use immunotherapy to cause the regression of tumors once they become established have been unsuccessful. The aim of this work was to understand the nature of this refractoriness in order to elaborate an efficient immunotherapeutic schedule. By employing a strong immunogenic murine fibrosarcoma (MC-C), we have demonstrated that MC-C tumor bearing mice can generate a T-cell mediated antitumor immune response which disappears when MC-C grows over 500 mm3. This tumor-associated immunosupression was accompanied with the emergence of a systemic inflammatory condition characterized by: a) an increased number of circulating and splenic granulocytes, most of them displaying activation and high expression of Gr1+ Mac1+ markers (n=6, p